• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    12/15/23 12:31:25 PM ET
    $AADI
    $ALRN
    $ASLN
    $BPTS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AADI alert in real time by email

    Gainers

    • Virpax Pharmaceuticals (NASDAQ:VRPX) stock rose 57.8% to $0.38 during Friday's regular session. The market value of their outstanding shares is at $4.4 million.
    • Verrica Pharmaceuticals (NASDAQ:VRCA) stock moved upwards by 51.06% to $5.68. The company's market cap stands at $238.9 million.
    • ASLAN Pharma (NASDAQ:ASLN) shares rose 26.98% to $0.63. The company's market cap stands at $10.5 million.
    • Biophytis (NASDAQ:BPTS) stock increased by 25.16% to $0.81. The company's market cap stands at $7.8 million.
    • Context Therapeutics (NASDAQ:CNTX) shares rose 24.94% to $1.05. The company's market cap stands at $16.7 million.
    • Immix Biopharma (NASDAQ:IMMX) shares increased by 24.51% to $7.07. The company's market cap stands at $140.5 million.

    Losers

    • Aadi Bioscience (NASDAQ:AADI) shares declined by 56.5% to $2.33 during Friday's regular session. The company's market cap stands at $57.2 million.
    • Aileron Therapeutics (NASDAQ:ALRN) shares fell 36.46% to $3.41. The company's market cap stands at $16.6 million.
    • Cingulate (NASDAQ:CING) shares fell 26.99% to $2.11. The market value of their outstanding shares is at $1.9 million.
    • Vapotherm (NYSE:VAPO) stock declined by 22.69% to $0.92. The market value of their outstanding shares is at $5.6 million.
    • SenesTech (NASDAQ:SNES) shares declined by 17.28% to $0.63.
    • IN8bio (NASDAQ:INAB) shares declined by 14.96% to $1.99. The market value of their outstanding shares is at $86.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AADI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AADI
    $ALRN
    $ASLN
    $BPTS

    CompanyDatePrice TargetRatingAnalyst
    Immix Biopharma Inc.
    $IMMX
    3/9/2026$23.00Mkt Outperform
    Citizens
    Immix Biopharma Inc.
    $IMMX
    2/9/2026$14.00Outperform
    Mizuho
    Context Therapeutics Inc.
    $CNTX
    9/18/2025$5.00Buy
    Guggenheim
    Context Therapeutics Inc.
    $CNTX
    4/21/2025Outperform
    William Blair
    Cingulate Inc.
    $CING
    1/10/2025$12.00Buy
    ROTH MKM
    Context Therapeutics Inc.
    $CNTX
    1/8/2025$4.00Mkt Outperform
    JMP Securities
    Context Therapeutics Inc.
    $CNTX
    11/25/2024$9.00Buy
    D. Boral Capital
    Verrica Pharmaceuticals Inc.
    $VRCA
    11/6/2024Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $AADI
    $ALRN
    $ASLN
    $BPTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Legal Officer, Corp. Sec Levit Alex C.

    4 - Context Therapeutics Inc. (0001842952) (Issuer)

    2/23/26 4:24:53 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Minai-Azary Jennifer Lynn

    4 - Context Therapeutics Inc. (0001842952) (Issuer)

    2/23/26 4:21:41 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Medical Officer Chagin Karen Deborah

    4 - Context Therapeutics Inc. (0001842952) (Issuer)

    2/23/26 4:18:52 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AADI
    $ALRN
    $ASLN
    $BPTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $56,667 worth of shares (31,346 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/13/26 5:20:17 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SVP and CFO Callahan Jennifer L. bought $24,515 worth of shares (4,864 units at $5.04), increasing direct ownership by 2,494% to 5,059 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AADI
    $ALRN
    $ASLN
    $BPTS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for YCANTH issued to VERRICA PHARMACEUTICALS INC

    Submission status for VERRICA PHARMACEUTICALS INC's drug YCANTH (ORIG-1) with active ingredient CANTHARIDIN has changed to 'Approval' on 07/21/2023. Application Category: NDA, Application Number: 212905, Application Classification: Type 5 - New Formulation or New Manufacturer

    7/21/23 4:54:32 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AADI
    $ALRN
    $ASLN
    $BPTS
    SEC Filings

    View All

    SEC Form 10-K filed by Verrica Pharmaceuticals Inc.

    10-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)

    3/11/26 8:11:55 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verrica Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)

    3/11/26 8:08:37 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by IN8bio Inc.

    SCHEDULE 13G - IN8BIO, INC. (0001740279) (Subject)

    3/2/26 2:01:20 PM ET
    $INAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AADI
    $ALRN
    $ASLN
    $BPTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citizens initiated coverage on Immix Biopharma with a new price target

    Citizens initiated coverage of Immix Biopharma with a rating of Mkt Outperform and set a new price target of $23.00

    3/9/26 9:07:22 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Immix Biopharma with a new price target

    Mizuho initiated coverage of Immix Biopharma with a rating of Outperform and set a new price target of $14.00

    2/9/26 7:01:42 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Context Therapeutics with a new price target

    Guggenheim initiated coverage of Context Therapeutics with a rating of Buy and set a new price target of $5.00

    9/18/25 8:39:06 AM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AADI
    $ALRN
    $ASLN
    $BPTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    – YCANTH® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40%, when compared to 2024 – – Company earned $35.6 million in total revenue in 2025, up from $7.6 million in the prior year – – YCANTH dispensed applicator units grew 99% to 51,296 in 2025 versus 25,773 units in 2024 – Company is advancing VP-315, its novel oncolytic peptide, toward a Phase 3 program for basal cell carcinoma in 2026, further analysis supports abscopal effects and tumor size reduction in untreated lesions – – First patient dosed in the first Phase 3 study of YCANTH for the treatment of common warts in December 2025, and Company expects to initiate

    3/11/26 8:00:00 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SenesTech to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, March 9, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, will report financial results for its fourth quarter and fiscal year 2025, ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Company has scheduled a conference call that same day, Thursday, March 12, 2026, at 5:00 pm ET, to review the results. Fourth Quarter and Fiscal Year 2024 Conference Call DetailsDa

    3/9/26 4:15:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026

    WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 11, 2026, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to di

    3/5/26 8:00:00 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AADI
    $ALRN
    $ASLN
    $BPTS
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Immix Biopharma Inc. on Jun 5

    Recent insider purchases at Immix Biopharma Inc. have caught the attention of investors, with Morris Gabriel S leading the way by acquiring $5,973 worth of shares on June 5, 2024. This transaction involved 3,300 units at a price of $1.81 per share, increasing Gabriel's direct ownership by 1% to 283,334 units, as reported in SEC Form 4. This move indicates Gabriel's confidence in the company's potential and may be seen as a positive signal by market participants. Click here for more details. Looking back at previous insider transactions, we can identify a few interesting patterns. On May 15, 2024, Rachman Ilya M purchased $9,660 worth of shares, comprising 4,300 units at $2.25 per share, whi

    6/10/24 1:09:24 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AADI
    $ALRN
    $ASLN
    $BPTS
    Leadership Updates

    Live Leadership Updates

    View All

    SenesTech Announces CEO Transition Plan

    Board To Initiate Search For New Leadership As Current CEO Plans Retirement Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition PHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.

    1/28/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Industry Veteran Bryan Downey Named Chief Commercial Officer NDA Accepted with May 2026 PDUFA Date Commercial Supply Agreement Executed KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to build a pipeline of next-generation products, today announced financial results for the quarter ended September 30, 2025, and provided recent corporate highlights. Recent Highlights (Post-Q3) FDA Accepts NDA for CTx-1301; PDUFA Date Set for May 31, 2026In October of 2025, the U.S. Food and Drug Administration (FDA) accepted Cingulate's New Drug Application

    11/13/25 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301

    Appointment builds on recent FDA acceptance of New Drug Application for review and advances Cingulate's transition toward commercialization pending FDA approval Company also strengthens its cash position by completing a $6 million financing KANSAS CITY, Kan., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™) drug-delivery platform, today announced the appointment of Bryan Downey as Chief Commercial Officer, following the U.S. Food and Drug Administration's (FDA) acceptance of Cingulate's New Drug Application (ND

    11/10/25 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AADI
    $ALRN
    $ASLN
    $BPTS
    Financials

    Live finance-specific insights

    View All

    SenesTech to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, March 9, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, will report financial results for its fourth quarter and fiscal year 2025, ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Company has scheduled a conference call that same day, Thursday, March 12, 2026, at 5:00 pm ET, to review the results. Fourth Quarter and Fiscal Year 2024 Conference Call DetailsDa

    3/9/26 4:15:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026

    WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 11, 2026, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to di

    3/5/26 8:00:00 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SenesTech Reports Third Quarter 2025 Financial Results with Record Revenue and Adjusted EBITDA

    77% Revenue Growth in Evolve® Rodent Birth Control™ Products Strong Cash Balance and Progress Toward Profitability SURPRISE, Ariz., Nov. 10, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-compliant Rodent Birth Control™ products today announced its financial results for the third quarter ended September 30, 2025. Q3 2025 Financial Highlights Revenues increased by 43% to $690,000, a record for the Company, from $482,000 in Q3 2024.Evolve® Rodent Birth Control product sales

    11/10/25 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $AADI
    $ALRN
    $ASLN
    $BPTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Verrica Pharmaceuticals Inc.

    SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

    12/9/24 6:22:49 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Verrica Pharmaceuticals Inc.

    SC 13D/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

    11/26/24 4:15:26 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials